Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Vantictumab |
Trade Name | |
Synonyms | anti-Fzd7|OMP-18R5 |
Drug Descriptions |
Vantictumab (OMP-18R5) is a monoclonal antibody that targets Frizzled receptors 1, 2, 5, 7, and 8, resulting in decreased Wnt signaling and potentially leading to decreased tumor growth (PMID: 22753465, PMID: 31338636). |
DrugClasses | WNT Inhibitor 16 |
CAS Registry Number | 1345009-45-1 |
NCIT ID | C96799 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Docetaxel + Vantictumab | Docetaxel Vantictumab | 0 | 1 |
Gemcitabine + Nab-paclitaxel + Vantictumab | Gemcitabine Nab-paclitaxel Vantictumab | 0 | 1 |
Gemcitabine + Vantictumab | Gemcitabine Vantictumab | 0 | 0 |
Paclitaxel + Vantictumab | Paclitaxel Vantictumab | 0 | 1 |
Vantictumab | Vantictumab | 1 | 0 |